Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial

Reuters12-11

Intensity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial

Intensity Therapeutics Inc. has announced the presentation of two posters at the 2025 San Antonio Breast Cancer Symposium (SABCS). The first poster, PS5-08-16, reports early observations from the INVINCIBLE-4 study, an ongoing randomized Phase 2 clinical trial investigating INT230-6 in combination with standard of care $(SOC)$ neoadjuvant immunochemotherapy in patients with early-stage triple negative breast cancer (TNBC). Preliminary data indicate that the INT230-6 cohort experienced 50% fewer grade 3 or higher adverse events compared to the SOC-alone cohort. Fourteen patients have been treated to date, with safety data for those receiving INT230-6 plus SOC remaining favorable. These results are being presented at the symposium. A second poster, PS4-10-15, outlines a potential Phase 3 clinical study design evaluating INT230-6 plus SOC, with and without the anthracycline doxorubicin, for breast cancer treatment. This presentation also takes place at the SABCS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43717) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590988515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590988515","market":"nz","top_or_hot":-1,"title":"Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Intensity Therapeutics Inc. has announced the presentation of two posters at the 2025 San Antonio Breast Cancer Symposium (SABCS). The first poster, PS5-08-16, reports early observations from the INVINCIBLE-4 study, an ongoing randomized Phase 2 clinical trial investigating INT230-6 in combination with standard of care <a href=\"https://laohu8.com/S/SOC\">$(SOC)$</a> neoadjuvant immunochemotherapy in patients with early-stage triple negative breast cancer (TNBC). Preliminary data indicate that the INT230-6 cohort experienced 50% fewer grade 3 or higher adverse events compared to the SOC-alone cohort. Fourteen patients have been treated to date, with safety data for those receiving INT230-6 plus SOC remaining favorable. These results are being presented at the symposium. A second poster, PS4-10-15, outlines a potential Phase 3 clinical study design evaluating INT230-6 plus SOC, with and without the anthracycline doxorubicin, for breast cancer treatment. This presentation also takes place at the SABCS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43717) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 20:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Intensity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Intensity Therapeutics Inc. has announced the presentation of two posters at the 2025 San Antonio Breast Cancer Symposium (SABCS). The first poster, PS5-08-16, reports early observations from the INVINCIBLE-4 study, an ongoing randomized Phase 2 clinical trial investigating INT230-6 in combination with standard of care <a href=\"https://laohu8.com/S/SOC\">$(SOC)$</a> neoadjuvant immunochemotherapy in patients with early-stage triple negative breast cancer (TNBC). Preliminary data indicate that the INT230-6 cohort experienced 50% fewer grade 3 or higher adverse events compared to the SOC-alone cohort. Fourteen patients have been treated to date, with safety data for those receiving INT230-6 plus SOC remaining favorable. These results are being presented at the symposium. A second poster, PS4-10-15, outlines a potential Phase 3 clinical study design evaluating INT230-6 plus SOC, with and without the anthracycline doxorubicin, for breast cancer treatment. This presentation also takes place at the SABCS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43717) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INTS","symbol_name":"Intensity Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL27R3GJ:1","article_id":"2590988515","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590988515","pubTimestamp":1765457238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Intensity Therapeutics Inc. has announced the presentation of two posters at the 2025 San Antonio Breast Cancer Symposium . The first poster, PS5-08-16, reports early observations from the INVINCIBLE-4 study, an ongoing randomized Phase 2 clinical trial investigating INT230-6 in combination with standard of care  neoadjuvant immunochemotherapy in patients with early-stage triple negative breast cancer . Preliminary data indicate that the INT230-6 cohort experienced 50% fewer grade 3 or higher adverse events compared to the SOC-alone cohort. Fourteen patients have been treated to date, with safety data for those receiving INT230-6 plus SOC remaining favorable. These results are being presented at the symposium. A second poster, PS4-10-15, outlines a potential Phase 3 clinical study design evaluating INT230-6 plus SOC, with and without the anthracycline doxorubicin, for breast cancer treatment. This presentation also takes place at the SABCS.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INTS":"Intensity Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Intensity Therapeutics报告2期三阴性乳腺癌试验早期结果良好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTS":0.9},"content_text":"Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial\n    \n\n        Intensity Therapeutics Inc. has announced the presentation of two posters at the 2025 San Antonio Breast Cancer Symposium (SABCS). The first poster, PS5-08-16, reports early observations from the INVINCIBLE-4 study, an ongoing randomized Phase 2 clinical trial investigating INT230-6 in combination with standard of care $(SOC)$ neoadjuvant immunochemotherapy in patients with early-stage triple negative breast cancer (TNBC). Preliminary data indicate that the INT230-6 cohort experienced 50% fewer grade 3 or higher adverse events compared to the SOC-alone cohort. Fourteen patients have been treated to date, with safety data for those receiving INT230-6 plus SOC remaining favorable. These results are being presented at the symposium. A second poster, PS4-10-15, outlines a potential Phase 3 clinical study design evaluating INT230-6 plus SOC, with and without the anthracycline doxorubicin, for breast cancer treatment. This presentation also takes place at the SABCS.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43717) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590988515","isCrawlerRequest":true}